Company news
Enlivex Ltd. (NASDAQ:ENLV) news
Enlivex Ltd. news releases on 6ix. Latest, Nov 22, 2021: Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
Press releases — page 3
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
November 21, 2021
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
November 9, 2021
Enlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells
October 4, 2021
Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis
October 3, 2021
Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS
September 21, 2021
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
August 8, 2021
Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant
August 1, 2021
Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant
July 11, 2021
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer
June 14, 2021
Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy
May 31, 2021
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis
May 17, 2021
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors
March 21, 2021
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies
March 7, 2021
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors
February 28, 2021
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
February 17, 2021
Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
February 15, 2021
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
February 11, 2021
Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
February 8, 2021
Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
February 2, 2021
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
December 6, 2020
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
December 2, 2020
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
November 17, 2020
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company’s Board of Directors
November 16, 2020
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy
November 4, 2020
Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients
November 2, 2020
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
October 21, 2020
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
September 30, 2020
Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy
September 15, 2020
Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy
August 24, 2020
Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
August 9, 2020
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
June 17, 2020
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
May 6, 2020
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
March 17, 2020
Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering
March 4, 2020
Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering
March 1, 2020
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
February 25, 2020
Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure
February 23, 2020
Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering
February 23, 2020
Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares
November 19, 2019
Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis
November 17, 2019
Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
November 3, 2019
Enlivex Announces Appointment of New Chief Executive Officer
October 23, 2019
European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment
October 7, 2019